GreyWolf Therapeutics 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GRWD5769 / GreyWolf Therapeutics
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1), ACTRN12623001077651: A clinical trial to determine the safety and tolerability of GRWD5769 in combination with anticancer treatments in patients with solid malignancies.

Recruiting
1/2
160
 
Grey Wolf Therapeutics Pty Ltd, Grey Wolf Therapeutics Pty Ltd
Advanced solid malignancies
 
 
EMITT-1, NCT06923761 / ACTRN12623000108617: (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Recruiting
1/2
300
Europe, RoW
Module 1 (GRWD5769 on its own as monotherapy), Module 2 (GRWD5769 in combination with cemiplimab, administered IV)
Grey Wolf Therapeutics, Grey Wolf Therapeutics Pty Ltd
Advanced Solid Malignancy
04/27
04/28
GRWD5769-ST-01, 2023-504845-30-00: A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies

Recruiting
1/2
175
Europe
GRWD5769, LIBTAYO 350 mg concentrate for solution for infusion.
Grey Wolf Therapeutics Limited, Grey Wolf Therapeutics Limited
Solid malignancies
 
 
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1), ACTRN12623000108617: A clinical trial to determine the safety and tolerability of GRWD5769 in patients with solid malignancies.

Active, not recruiting
1
60
 
Grey Wolf Therapeutics Pty Ltd, Grey Wolf Therapeutics Pty Ltd
Advanced solid malignancies
 
 

Download Options